Sign in
CompletedNo phase

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

Key facts

Who runs it
Nanjing First Hospital, Nanjing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
579 people enrolled
Started
15 Jun 2024
Ended
10 Jan 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
  • Vonoprazan+Amoxicillin
  • Vonoprazan+doxycycline
Record updated
4 March 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18-65 years old
  • Patients confirmed to be positive for H. pylori by 13C-UBT or 14C-UBT
  • Patients who have not received Helicobacter pylori eradication therapy before, or patients who have failed to eradicate in the early stage but have not received eradication therapy within half a year
  • Voluntarily join this trial and sign the informed consent form

Who cannot take part

  • Patients who have received Helicobacter pylori eradication therapy within half a year
  • Use of antibiotics, bismuth, and histamine H2 receptor antagonists or PPIs for the first 2 weeks before starting study treatment
  • Use of adrenocorticosteroids, non-steroidal anti-inflammatory drugs, anticoagulants, barbiturates, phenytoin, or carbamazepine drugs
  • Suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease
  • Allergy to the study drug (penicillin, amoxicillin, Vonoprazan, doxycycline, etc.)
  • Patients with confirmed active peptic ulcer
  • History of esophageal or gastric surgery
  • Hepatic insufficiency caused by hepatitis, fatty liver and other reasons
  • Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases
  • Pregnant or lactating women
  • Alcoholism

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

It is planned to select Hp infection patients in a number of tertiary hospitals in Jiangsu and randomly divide them into three groups: group A is the classic group, receiving Vonoprazan 20mg, bid + amoxicillin 1.0g, bid + doxycycline 0.1g, bid + colloidal pectin bismuth 0.3g, bid and group C are double groups, respectively, receiving standard dose amoxicillin (1.0 g, bid) combined with vonorrasan dual regimen and doxycycline (0.1g, bid) combined with Vonoprazan dual regimen, the treatment course of the three groups was 14 days, and the oral dose of Vonoprazan was 20mg, bid, the eradication rate, adverse reactions, compliance and other aspects of the three groups were compared, In order to obtain a safe, efficient, economical and convenient Hp eradication program with a wider range of applications.

The 3 groups in the trial

  • Group A Bismuth quadrupleExisting treatment, for comparison

    Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth, treatment course 14 days

    Treatment: Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days

  • Group B Amoxicillin Dual therapyTreatment being tested

    Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid , treatment course 14 days

    Treatment: Vonoprazan+Amoxicillin

  • Group C doxycycline Dual therapyTreatment being tested

    Vonoprazan 20 mg, bid +doxycycline 0.1 g, bid,treatment course 14 days

    Treatment: Vonoprazan+doxycycline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication:A Prospective, Multicenter, Open-label Randomized Controlled Study
Record updated
4 March 2026